Biotech-Pharmaceutical Alliances as aSignal of Asset and Firm Quality*

Loading...
Thumbnail Image
Penn collection
Health Care Management Papers
Degree type
Discipline
Subject
Marketing
Medical Education
Pharmacy Administration, Policy and Regulation
Funder
Grant number
License
Copyright date
Distributor
Author
Nicholson, Sean
Danzon, Patricia. M
McCullough, Jeffrey
Contributor
Abstract

We examine the determinants of biotech-pharmaceutical alliance prices to determine whether the market for alliances is characterized by asymmetric information. We find that inexperienced biotech companies receive substantially discounted payments when forming their first alliance. A jointly developed drug is more likely to advance in clinical trials than a drug developed by a single company, so the first- deal discount is not consistent with the drug’s subsequent performance. Biotech companies receive substantially higher valuations from venture capitalists and the public equity market after forming their first alliance, which implies that alliances send a positive signal to prospective investors.

Advisor
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Publication date
2005-07-01
Journal title
Journal of Business
Volume number
Issue number
Publisher
Publisher DOI
Journal Issue
Comments
Recommended citation
Collection